Bristol Myers Squibb Company $BMY Stock Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

Posted by Brenda Bartman on Oct 31st, 2026

VIRGINIA RETIREMENT SYSTEMS ET Al lowered its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 10.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,540,730 shares of the biopharmaceutical company’s stock after selling 181,500 shares during the period. Bristol Myers Squibb makes up 0.6% of VIRGINIA RETIREMENT SYSTEMS ET Al’s investment portfolio, making the stock its 25th largest holding. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Bristol Myers Squibb were worth $96,142,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. State Street Corp increased its position in Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after buying an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA bought a new position in Bristol Myers Squibb during the 2nd quarter valued at approximately $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Bristol Myers Squibb by 0.5% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock valued at $1,315,984,000 after buying an additional 119,690 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Bristol Myers Squibb by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock valued at $1,137,847,000 after buying an additional 520,330 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

BMY has been the topic of a number of recent research reports. TD Cowen began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating on the stock. Cantor Fitzgerald reduced their price target on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a report on Thursday, October 8th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Piper Sandler dropped their price target on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a research note on Monday, October 26th. Finally, Leerink Partners downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $73.00 to $59.00 in a research report on Monday, October 5th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $65.46.

Read Our Latest Stock Report on Bristol Myers Squibb

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $62.46 on Friday. The business’s fifty day simple moving average is $62.80 and its two-hundred day simple moving average is $59.94. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 12 month low of $45.20 and a 12 month high of $68.64. The company has a market cap of $127.59 billion, a price-to-earnings ratio of 13.85, a P/E/G ratio of 0.32 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.25. The firm had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. Bristol Myers Squibb had a return on equity of 62.78% and a net margin of 18.47%. The company’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.63 earnings per share. Research analysts anticipate that Bristol Myers Squibb Company will post 6.37 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. Bristol Myers Squibb’s payout ratio is 55.51%.

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.